Kornimate/medical-research-clean huggingface dataset:
a study of pulmozyme® (dornase alpha) in 3- to 5-year-old patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this was a phase iv, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the effect of pulmozyme on pulmonary function, health-related quality of life (hrqol), and respiratory symptoms in 3- to 5-year-old children with cystic fibrosis (cf). approximately 40 patients were planned to be enrolled in this study. however, only 3 patients were eligible for random allocation and received treatment: 1 patient in the pulmozyme group and 2 patients in the placebo group. all 3 patients completed the study assessments but did not have usable pulmonary function test (pft) data.


Eligibility criteria:
inclusion criteria: * signed informed consent form * aged 3-5 years * diagnosis of cystic fibrosis exclusion criteria: * children taking scheduled inhaled pulmozyme or hypertonic saline within 56 days prior to visit 1 or any pulmozyme in the 28 days before visit 1 * involvement in a clinical intervention trial within the 4 weeks prior to visit 1 * use of an investigational drug or device within 28 days prior to visit 1 * any other condition that might increase the risk of participation to the patient in the judgement of the investigator

Keywords: pulmozyme cf
clinical study of gastric cancer, colorectal cancer and bladder cancer based on liquid biopsy

Conditions: Gastric Cancer; Colorectal Cancer; Bladder Cancer

Summary: gastric cancer and colorectal cancer are common gastrointestinal malignancies in the world.early cancer generally has no obvious symptoms. endoscopy is the "gold standard"for the diagnosis of gastric cancer and colorectal cancer.gastric cancer and colorectal cancer treatment mainly includes surgery and medication.compared with traditional diagnosis and treatment methods, the application of gene detection technology, especially high-throughput sequencing technology (ngs) in tumor diagnosis and treatment, performs multi-dimensional and multi-target detection of cancer-related genes, which can quickly and accurately determine the target gene mutations morphology and expression differences, so as to provide personalized guidance to patients in terms of medication, treatment or prognosis evaluation, which can save a lot of time and treatment costs, and improve the overall treatment effect and patient quality of life. cystoscopy and biopsy sampling pathological testing are the gold standard for bladder cancer diagnosis, and have been widely used in clinical diagnosis and prognosis judgment. however, cystoscopy is cumbersome, expensive, and often causes pain to the patients under test. at present, the main clinical non-invasive detection technique for bladder cancer is still the cytological examination of urinary tract bladder cells in urine, and its sensitivity and specificity are not good, especially for the diagnosis of early lower grade bladder cancer.for bladder cancer, tumor tissue (puncture biopsy or surgical resection) dna, urine ctdna, urinary tract exfoliated cell dna and peripheral blood ctdna can be used for genetic testing, but the consistency of the genetic testing results of these four types of samples has not been verified, especially there is no systematic evaluation of the guidance effect of non-invasive gene detection of free tumor dna and urinary tract shed cell dna in the diagnosis and treatment of bladder cancer.the corresponding relationship between the significant mutation genes contained in the dna derived from bladder urinary tract cancer and the various types and stages of bladder cancer is not clear.


Eligibility criteria:
inclusion criteria: * patients who are scheduled for gastric tumor, colorectal tumor or bladder tumor resection signed informed consent exclusion criteria: * the vital signs are not stable unconscious unwilling to cooperate
kinect-based upper limb rehabilitation system in stroke patients

Conditions: Stroke; Hemiplegia; Virtual Rehabilitation

Summary: the investigators have developed the kinect-based upper extremity rehabilitation program and designed this protocol to prove the efficacy of this program. in brief, subacute stroke patients allocated to intervention group will receive the kinect based-rehabilitation program plus conventional occupational therapy and patients allocated to control group will receive the sham virtual rehabilitation plus conventional occupational therapy, for 10 days. 20 patients with subacute stroke will be allocated into each group and after completing the 10 days intervention, they will be assessed by using objective assessment tools for upper extremity function.


Eligibility criteria:
inclusion criteria: * age from 20 to 80 years * stroke within prior 3 months * unilateral upper extremity weakness exclusion criteria: * uncontrolled medical conditions * who cannot obey the simple command * who has the hemispatial neglect, visual impairment, apraxia
baerveldt 350 vs ahmed clearpath 250 for the treatment of glaucoma

Conditions: Glaucoma

Summary: to compare the safety and efficacy of baerveldt 350 and ahmed clearpath 250 tube shunts in lowering iop in glaucoma patients.

tube shunt implantation is a common type of surgery considered standard of care for treating significant potentially-blinding glaucoma where medical and laser treatment, and previous surgeries, have failed to control intra-ocular pressure (iop) sufficiently to stop glaucoma progression towards blindness. since a larger plate tube (e.g., baerveldt 350) is more difficult to implant requiring longer surgical time and intraoperative ocular muscle manipulation with possible patient discomfort, a smaller plate tube shunt (e.g., ahmed clearpath 250) requiring shorter surgical time and no ocular muscle manipulation may have an advantage if the long term surgical outcomes were the same. however, the literature is lacking regarding the effect of the tube plate size on the final outcomes of tube shunt implantation. most published comparisons are between totally different types of tube shunts regardless of plate size, often made of different materials, often comparing valved vs. non-valved tube shunts,combining different plate sizes in the same study groups,5 mixing tubes with or without combined cataract surgery in the same study groups, or comparing surgeries performed by several surgeons utilizing different surgical methods. further, all these studies utilize tubes implanted into the anterior chamber (ac) thus increasing the risk of corneal failure, with no comparisons at all between tube shunts implanted through the ciliary sulcus of the eye designed to reduce the risk of corneal failure. our principle investigator (aw) is specializing and well-published in this type of tube shunt implantation. this prospective randomized trial is designed to resolve all these confusing factors in the literature and finally provide the answer of whether tube plate size has an effect on the final outcomes of tube shunt implantation by performing a "clean" study that would isolate the effect of tube plate size on long term outcomes. to achieve this goal our study will utilize two non-valved tube shunts with a different plate size (350 vs. 250 mm2) made of identical materials, in eyes that have already had cataract surgery, and all performed by the same surgeon (aw) through the ciliary sulcus.

Eligibility criteria:
inclusion criteria: * significant uncontrolled glaucoma despite medical, laser or previous surgical therapy that requires tube shunt implantation as standard-of-care to stabilize the glaucoma and preserve vision. * pseudophakia * patients who are willing to participate and are able to understand and sign the study consent form. * age ≥18 years. exclusion criteria: * phakic eyes (no previous cataract surgery). * aphakic eyes (status post previous cataract removal but without a lens implant). * age \<18 years. * women of child-bearing age. * patients unable to comprehend and sign the study consent form. * women who are pregnant.

Keywords: glaucoma baerveldt 350 ahmed clearpath 250
pigment dispersion syndrome: natural history and possible protective effect of a yag laser iridotomy

Conditions: Pigment Dispersion Syndrome

Summary: study aims 1. to determine the 10-year conversion rate from pigment dispersion syndrome (pds) to pigmentary glaucoma (pg) 2. to evaluate the possible protective effect of a yag-laser iridotomy

1154 workers in the parma area will be screened for eligibility to long-term use of video-monitors. those referred to the glaucoma clinic for suspected pds will be enrolled in the study. in a prospective study on the natural history of pds and pg, richter et al. (arch ophtal 104:211-5, 1986) found an association between "active pigment dispersion" and elevated iop. therefore, in order to evaluate the "stability" of the pigment, a phenylephrine test will be performed following the method reported by epstein et al (1978) ajo 85:43-50. the test will be performed by one investigator (sag)and was considered positive if \> "grade 1+" (i.e. at least 10 particles in a single light beam). eyes showing a positive test will be considered as "high-risk" for conversion to pg. yag laser iridotomy will be performed in patients showing both eyes at high risk. one eye only (randomly chosen) will be treated. the fellow eye will be left untreated and considered as internal control. low risk eyes will be followed without any intervention.

Eligibility criteria:
inclusion criteria: * krukenberg spindle * slit-like mid peripheral iris defect * pigment in \> 270° of ac angle exclusion criteria: * iop \> 18 mmhg * pex (full mydriasis) * w/w field defect (octopus g1 program)

Keywords: glaucoma pigmentary glaucoma laser iridotomy
study to evaluate the safety and efficacy of hi-brite large diameter rigid gas permeable contact lens

Conditions: Refractive Errors

Summary: study to evaluate the safety and efficacy of hi-brite large diameter rigid gas permeable contact lens (hexafocon b) test when worn on a daily wear basis in the correction of myopia/hyperopia/astigmatism/presbyopia/ and irregular cornea.

subjects who meet all eligible requirements for entry into the study will be instructed to insert the hi-brite large diameter rigid gas permeable contact lens in daily wear basis for clinical evaluation purposes. treatment period: 6 months

Eligibility criteria:
inclusion criteria: * ametropic or irregular cornea subjects who need to wear spectacle lens or contact lens in their daily life. * is of age at least 20 years old and no older than 65 years old capacity to volunteer. * has read and signed the informed consent form or waiver. (4) has myopia or hyperopia -20.00d～+20.00d, astigmatism -0.25\~-4.00d, or presbyopia +1.00d～+3.50d. * irregular cornea subjects include keratoconus, high astigmatism (\>-4.00d) or post-refractive surgery patients. * no active ocular disease, infection or any disorder of eyelids and conjunctiva. * has reasonable expectation of improvement in visual acuity with the test lenses. * is willing and able to follow subject instructions and meet the protocol -specified visit schedule. (if subjects missed any visit, they must be discontinued from the study.) (9) agrees to wear the test lenses at a daily wear basis. (10) willing to adapt wearing gp contact lens. exclusion criteria: the subject is ineligible for entry into the study if the subject * has any systemic disease affecting ocular health. * is using any systemic or topical medications that will, in the investigator's opinion. affect ocular physiology or lens performance within one (1) week before entering this study. * has an active ocular disease or has ever used systemic steroid or any other medicine that may affect significant on vision or healing. * has any grade 2 or greater finding listed in the quantification of slit lamp observations form. subjects with corneal infiltrates, however, of any grade, are not eligible. * has any "present" finding listed in the quantification of slit lamp observations that, in the investigators' judgment, interferes with contact lens wear. * has any scar or neovascularization within the central 4mm of the cornea. subjects with minor peripheral corneal scarring that, in the investigator's judgment, does not interfere with contact lens wear are eligible for this study. * severe dry eye (schirmer test\<5mm/5min) * corneal keratitis * is aphakic * had undertaken the following surgery: retina, glaucoma, cataract surgery. * is amblyopic, bscva can't achieve (include) 20/40(0.5) when wear trial lenses. * allergy to contact lens solution. * ls participating in any other clinical research study. * pregnancy or breast-feeding.

Keywords: myopia scleral lens astigmatism presbyopia
short term postoperative tamponade using perfluorocarbon liquid for giant retinal tears

Conditions: Retinal Detachment

Summary: the purpose of the article is, to investigate the efficacy and safety of perfluorocarbon liquid (pfcl) ,as a short term postoperative tamponade for treating retinal detachment ,associated with giant retinal tears.

a retrospective study wich compared 2 groups that had giant tear repair in one group, pfcl was left for few days as an intermediate measure until silicone oil or sf6 gas was used to reattach the retina ,and in the control group sf6 or silicone oil were used, with no pfcl.

Eligibility criteria:
inclusion criteria: * above 18 years of age * retinal tear at least of 3 clock hours. exclusion criteria: * less than 18 years of age * retinal tear less than 3 hours
clearance of 25-hydroxyvitamin d3 during vitamin d3 supplementation

Conditions: Chronic Kidney Disease

Summary: the goal of this study is to determine how 25(oh)d3 clearance is affected by vitamin d3 supplementation using a gold standard pharmacokinetic approach.

we expect that this study will enhance interpretation of available diagnostic tests, inform the results of ongoing large clinical trials of vitamin d supplements, and help develop new strategies to target vitamin d to improve health.

Eligibility criteria:
inclusion criteria: * successful prior completion of related protocol clear (nct02937350) or clear-cf (nct03104855) * age ≥ 18 years * self-reported race caucasian, african american, or african exclusion criteria: * primary hyperparathyroidism * gastric bypass * tuberculosis or sarcoidosis * current pregnancy * child-pugh class b or c cirrhosis (i.e. cirrhosis with ascites, hepatic encephalopathy, bilirubin \>=2 mg/dl, serum albumin \ = 4 seconds) * history of kidney transplantation (unless failed transplant now treated with hemodialysis) * use of 1,25(oh)2d3 or an analogue, calcimimetics, or medications known to induce cyp24a1 within 4 weeks (wash-out allowed) * serum calcium \> 10.1 mg/dl * hemoglobin \< 10 g/dl

Keywords: chronic kidney disease vitamin d catabolism
persistent pain induced by uniportal video-assisted thoracic surgery

Conditions: Post-thoracotomy Pain Syndrome

Summary: the investigators investigate the prevalence of ptps in patients receiving with uniportal video-assisted thoracic surgery (vats), and early identify neuropathic pain as well as treated with neural protective strategy to target intercostal nerve.

more than 30% of patients have persistent pain after thoracic surgery. intercostal neuralgia is characterized by neuropathic pain in the distribution of affected intercostal nerve(s) (along the ribs, chest, or abdomen) that commonly manifests as a sharp, aching, radiating, burning, or stabbing pain and may be associated with paresthesia such as numbness and tingling. the pain may be intermittent or constant and typically presents as a band-like pain that is wrapped around the chest and back or in a thoracic dermatomal pattern. pain may last for a prolonged period and may continue long after the disease process has subsided. hypertonic dextrose injection (prolotherapy) is reported to reduce pain, including non-surgical chronic low back pain (clbp), and subcutaneous injection of 5% dextrose is said to minimize neurogenic pain hyperalgesia and allodynia. the mechanism in both cases is unclear, though a direct effect of dextrose on neurogenic pain has been proposed. this study assessed the short-term analgesic effects of epidural 5% dextrose injection compared with saline for non-surgical clbp. intercostal nerve damage is a suspected pathogenic mechanism for developing post-thoracotomy pain syndrome (ptps). video-assisted thoracic surgery (vats) is a minimally invasive procedure that potentially reduces ptps. however, there was no specific outcome study for uniportal vats. in this study, the investigators investigate the prevalence of ptps in patients receiving uniportal video-assisted thoracic surgery (vats), identify neuropathic pain early, and treat it with a neural protective strategy to target intercostal pain nerve.

Eligibility criteria:
inclusion criteria: * ptps after single port vats exclusion criteria: * abnormal sensation * can not complete questionnaire * others cause of pain
the visceral analgesic effect of erector spinae plane block in laparoscopic cholecystectomy

Conditions: Visceral Pain, Postoperative

Summary: the purpose of this study was to investigate the effectiveness of erector spinae plane block on postoperative visceral pain in laparoscopic cholecystectomy (llc). given that rectus sheath block may provide sufficient somatic pain block, investigators aimed to investigate whether erector spinae block is effective in visceral pain block. after induction of general anesthesia, group of patient is decided randomly. in group r, rectus sheath block is performed with 0.2% ropivacaine 30ml before the operation. in group re, rectus sheath block and erector spinae plane block are performed with 0.2% ropivacaine 70ml before the operation. nrs score measurement and comparison of the rescue analgesic dose used at 0, 0.5, 1, 2,6, 12, 18, and 24 hours after arrival at the recovery room were collected


Eligibility criteria:
inclusion criteria: 1. adults between the ages of 20 and 80 2. scheduled laparoscopic cholecystectomy patient 3. american society of anesthesiologists score 1 or 2 4. patients who have voluntarily agreed in writing to participate in the trial exclusion criteria: 1. patient with side effects on local anesthetics or steroids 2. patient who are taboo of peripheral nerve block such as blood clotting disorder, infection, etc. 3. patients with uncontrolled medical or psychiatric problem 4. patient does not agree to participate in the study 5. patients with deformity at vertebra or chest wall. 6. patients who are pregnant or lactating 7. patients receiving a single laparoscopic cholecystectomy (including using a robot) 8. patients with severe intraperitoneal adhesion (higher than nair s grade 3), or with external drain.

Keywords: laparoscopic cholecystectomy erector spinae plane block visceral pain
relinking diagnosed but untreated hcv patients back into care.

Conditions: Hepatitis C Virus Infection

Summary: reintroduction of patients into a hcv infection care pathway after a positive chronic hepatitis c diagnosis by previous testing in our hospital who were lost in follow-up. gaining insight in the possible reasons why patients are lost in follow-up after positive hepatitis c serology.


Eligibility criteria:
inclusion criteria: * positive hcv serology between 2012-2022 with positive or uknown hcv rna in uz brussels database * ≥18 years exclusion criteria: * positive hcv serology with negative hcv rna * previously eradicated patients in uz brussel
efficacy and safety of semaglutide ingection in subjects with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: to evaluate the similarity of the efficacy and safety of semaglutide injection (qlg2065) vs. ozempic® in patients with type 2 diabetes mellitus (t2dm) with poor blood glucose control after metformin treatment.


Eligibility criteria:
inclusion criteria: 1. male or female, age ≥ 18 years and ≤75 years old at the time of screening. 2. subjects diagnosed with type 2 diabetes for at least 6 months (who, 1999) 3. within 60 days before screening, subjects received stable treatment with only metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day), or receive combination metformin (dose ≥ 750 mg/day) and another oad (alpha-glucosidase inhibitors, sulfonylureas, glinides, sglt-2i or thiazolidinedione), stable treatment is defined as unchanged medication and daily doses; 4. at the time of screening, for those who have previously been treated with metformin alone, hba1c ≥ 7.0% and ≤ 11.0%（local lab）; for those who have previously used metformin in combination with another oad treatment, hba1c ≥ 7.0% and ≤10.0%（local lab）; 5. bmi≥18.5kg/m2 and ≤35 kg/m2 6. subjects voluntarily participate in this research, can communicate well with researchers, are willing to maintain the same diet and exercise habits throughout the study, and sign an informed consent form (icf) . 7. at baseline，hbalc ≥ 7.0% and ≤ 11.0%（cental lab） exclusion criteria: 1. known or suspected hypersensitivity to any glp-1ra or related products, or allergic constitution 2. treatment with glp-1ra, dpp-4 inhibitor, or insulin in a period of 60 days before screening. an exception is short-term insulin therapy (≤7 days in total). 3. history of chronic or acute pancreatitis 4. screening calcitonin value ≥ 50 ng/l (pg/ml) 5. personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men 2) 6. have a history of major cardiovascular and cerebrovascular diseases within 90 days before screening. 7. known proliferative retinopathy or maculopathy
hm15136 (efpegerglucagon) treatment for 8 weeks in subjects aged ≥2 years with congenital hyperinsulinism (chi)

Conditions: Congenital Hyperinsulinism

Summary: this study is designed to evaluate the safety, tolerability, pharmacokinetics (pk), and efficacy of hm15136 when used as add-on therapy in subjects with chi with persistent hypoglycemia while on standard of care treatment (soc). hm15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.


Eligibility criteria:
inclusion criteria: * male and female subjects aged ≥2 years with chi with persistent hypoglycemia despite current soc treatment according to the investigator's evaluation or documentation * stable therapy with soc medications with or without nutritional supplementation * previously undergone near-total pancreatectomy or being treated with a nonsurgical approach, having been evaluated as not eligible for pancreatic surgery * hba1c \<7% exclusion criteria: * subjects with type 1 or type 2 diabetes mellitus * other reasons for hypoglycemia, including but not limited to drug-induced hyperinsulinemic hypoglycemia, etc * treatment of chi with continuous intravenous glucose or glucagon infusion within 3 months prior to screening * subjects with current use of any drugs that are known to interfere with the study drug, glucose metabolism, or study procedures (eg, use of systemic glucocorticoids \[excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled forms\] or insulin) * have conditions that could affect glucose levels such as pheochromocytoma, insulinoma, and glucagonoma